The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets
Open accessThe DOI matches its Crossref record; 48 of the 50 references it cites were found in a registry or an index.
Abstract
The incretins glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) mediate insulin responses that are proportionate to nutrient intake to facilitate glucose tolerance 1 . The GLP-1 receptor (GLP-1R) is an established drug target for the treatment of diabetes and obesity 2 , whereas the therapeutic potential of the GIP receptor (GIPR) is a subject of debate. Tirzepatide is an agonist at both the GIPR and GLP-1R and is a highly effective treatment for type 2 diabetes and obesity 3,4 . However, although tirzepatide activates GIPR in cell lines and mouse models, it is not clear whether or how dual agonism contributes to its therapeutic benefit. Islet beta cells express both the GLP-1R and the GIPR, and insulin secretion is an established mechanism by which incretin agonists improve glycemic control 5 . Here, we show that in mouse islets, tirzepatide stimulates insulin secretion predominantly through the GLP-1R, owing to reduced potency at the mouse GIPR. However, in human islets, antagonizing GIPR activity consistently decreases the insulin response to tirzepatide. Moreover, tirzepatide enhances glucagon secretion and somatostatin secretion in human islets. These data demonstrate that tirzepatide stimulates islet hormone secretion from human islets through both incretin receptors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“A recent study utilizing a GIPR-blocking antibody conjugated with a potent GLP-1R agonist in obese subjects, has reignited interest in such multi-mode therapy174.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [174]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“So far we know tirzepatide drives insulin secretion primarily via GIPR in human islets [108].”
From Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes (2024) · cites this paper as [108]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“GLP-1 and GIP both contribute to incretin re sponses (31), and GIP receptors are important for the incretin action of tirzepatide (32).”
From Effects of Tirzepatide vs Semaglutide on β-Cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test (2024) · cites this paper as [32]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The sustained body weight-lowering efficacy at monthly doses that are more than a hundred-fold higher than that commonly employed with selective GLP-1 agonists, without gastrointestinal adverse effects, is difficult to explain.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [174]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 3×
“05 nM radioligand (Human/Mouse [125I] GLP-1(7-36)NH2 and Human [125I]GIP(1-42)OH; both PerkinElmer >2,200 Ci mmol, >95% purity) was added to peptide in 100 μl assay buffer (concentration–response curves in DMSO, final concentration of 0.”
BackgroundMethodTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096 · cited 4×
“05 nM radioligand (Human/Mouse [125I] GLP-1(7-36)NH2 and Human [125I]GIP(1-42)OH; both PerkinElmer >2,200 Ci mmol, >95% purity) was added to peptide in 100 μl assay buffer (concentration–response curves in DMSO, final concentration of 0.”
BackgroundMethodInfluentialGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868 · cited 4×
“05 nM radioligand (Human/Mouse [125I] GLP-1(7-36)NH2 and Human [125I]GIP(1-42)OH; both PerkinElmer >2,200 Ci mmol, >95% purity) was added to peptide in 100 μl assay buffer (concentration–response curves in DMSO, final concentration of 0.”
BackgroundMethodInfluentialSelf-citationNauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651 · cited 4×
“We first used islets isolated from mice with selective deletion of the Gipr in beta cells in combination with the GLP-1R antagonist exendin(9-39) (Ex9).”
BackgroundMethodInfluentialPharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500 · cited 4×
“05 nM radioligand (Human/Mouse [125I] GLP-1(7-36)NH2 and Human [125I]GIP(1-42)OH; both PerkinElmer >2,200 Ci mmol, >95% purity) was added to peptide in 100 μl assay buffer (concentration–response curves in DMSO, final concentration of 0.”
BackgroundMethodInfluentialSelf-citationCoskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
Self-citationUnimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696 · cited 4×
“We first used islets isolated from mice with selective deletion of the Gipr in beta cells in combination with the GLP-1R antagonist exendin(9-39) (Ex9).”
BackgroundMethodInfluentialSelf-citationTirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J. C., Stutsman, C., Cardona, G. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140532 · Cited by 541 · cited 4×
“We first used islets isolated from mice with selective deletion of the Gipr in beta cells in combination with the GLP-1R antagonist exendin(9-39) (Ex9).”
BackgroundMethodInfluentialSelf-citation
Research works printed but not linked: 1
- Sparre-Ulrich, A. H. et al. GIP(3-30)NH2 is a potent competitive antagonist of the GIP receptor and effectively inhibits GIP-mediated insulin, glucagon, and somatostatin release. Biochem. Pharmacol. 131, 78–88 (2017). · DOI · Paper page
Cited by
GLP-1-based therapies for diabetes, obesity and beyond
Drucker, D. J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01183-8 · Cited by 236
“Tirzepatide potentiates insulin secretion via activation of both the GIPR and the GLP-1R in human islets 34 .”
Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022.
Watanabe, J. H., Kwon, J., Nan, B., & Reikes, A. (2024) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2023.10.002 · Cited by 216
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
Huttasch, M., Roden, M., & Kahl, S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155937 · Cited by 169
Campbell, J. E., Müller, T. D., Finan, B., DiMarchi, R. D., Tschöp, M. H., & D’Alessio, D. A. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.07.010 · Cited by 149
Self-citationTransforming obesity: The advancement of multi-receptor drugs
Kusminski, C. M., Perez-Tilve, D., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Scherer, P. E. (2024) · Cell · doi:10.1016/j.cell.2024.06.003 · Cited by 126
Self-citation
Metadata
- Authors
- El, K., Douros, J. D., Willard, F. S., Novikoff, A., Sargsyan, A., Perez-Tilve, D., Wainscott, D. B., Yang, B., Chen, A., Wothe, D., Coupland, C., Tschöp, M. H., Finan, B., D’Alessio, D. A., Sloop, K. W., Müller, T. D., & Campbell, J. E.
- Affiliations
- Duke University (US)
- Eli Lilly (United States) (US)
- Helmholtz Munich (DE)
- Corresponding author
- Sloop, Kyle W.
- Müller, Timo D.
- Campbell, Jonathan E.
- ORCID
- Venue
- Nature Metabolism
- Published
- 2023-06-05
- Volume
- 5
- Issue
- 6
- Pages
- 945-954
- ISSN
- 2522-5812 (ISSN-L)
- PMC
- PMC10290954
- OpenAlex
- W4379471679
- Cited by
- 118
- References
- 50
- Citations by year
- 2026: 23 · 2025: 42 · 2024: 38 · 2023: 15
- FWCI
- 32.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Metabolism (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion, cc-by)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Funders
- Eli Lilly and Company
- Leona M. and Harry B. Helmsley Charitable Trust
- Deutsche Forschungsgemeinschaft (DFG-TRR296, GRK2816/1, TRR- 152, SFB1123, TRR296, TRR152, TRR296)
- Novo Nordisk
- National Institutes of Health (DK046492)
- Helmholtz Zentrum München
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK125353, DK123075, R01DK123075, R37DK046492, DK125353, DK046492, R01DK046492, T32DK007012, K01DK132461)
- H2020 European Research Council (695054)
- HORIZON EUROPE European Research Council (101044445)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- tirzepatide, GIP receptor, GLP-1 receptor, insulin secretion, human pancreatic islets, glucagon secretion, somatostatin secretion, type 2 diabetes, obesity, incretin signaling
- MeSH terms
- Glucagon-Like Peptide Receptors, Tirzepatide, Animals, Cells, Cultured, Gastric Inhibitory Polypeptide, Humans, Hypoglycemic Agents, Insulin, Islets of Langerhans, Mice, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets. https://app.cochat.ai/papers/10.1038/s42255-023-00811-0
- The paper
- El, K., Douros, J. D., Willard, F. S., Novikoff, A., Sargsyan, A., Perez-Tilve, D., Wainscott, D. B., Yang, B., Chen, A., Wothe, D., Coupland, C., Tschöp, M. H., Finan, B., D’Alessio, D. A., Sloop, K. W., Müller, T. D., & Campbell, J. E. (2023). The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets. Nature Metabolism. https://doi.org/10.1038/s42255-023-00811-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.